Clinical trials: Hypertensive Kidney Disease
Hypertension
Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease
This study is a post-marketing surveillance in Japan, and it is a local prospective, company sponsored and observational study of patient who have been treated by Adalat CR for hypertension with diabetes and/or chronic kidney…
- Trial name
- NCT01363336
- Testing
- Nifedipine (Adalat CR, BAYA1040)
- Where
- Japan
- Volunteers
- 1,882 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt Nephropathy
This study will assess the optimal renoprotective dose of Aliskiren in hypertensive type 2 diabetes patients with incipient or overt nephropathy
- Trial name
- NCT00464776
- Testing
- Aliskiren
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Novartis
Hypertension
A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment
This study is a multi-center, open label, dose titration, exploratory study to evaluate efficacy and safety of CS-3150 in Japanese hypertensive patients with moderate renal impairment.
- Trial name
- NCT02448628
- Testing
- CS-3150
- Where
- Japan
- Volunteers
- 33 people
- Sponsor
- Daiichi Sankyo
Hypertension
National Survey on Hypertension
Describe the clinical characteristics of hypertensive patients aged of 75 years and older seen in general practitioner consultation according to their renal damage
- Trial name
- SERENITE (NCT00804167)
- Where
- 1,291 sites in France
- Volunteers
- 4,500 people
- Sponsor
- AstraZeneca
Hypertension
ConfidenHT System for Diagnostic Electrical Mapping of Renal Nerves
To evaluate the safety and performance of the ConfidenHT System
- Trial name
- RDN (NCT02777216)
- Testing
- ConfidenHT system
- Where
- 3 sites in Greece, Netherlands
- Volunteers
- 20 people
- Sponsor
- BlueWind Medical
Hypertension
A Study to Describe Vascular and Renal Effects and Safety of Valsartan in Patients With High Blood Pressure
One hundred twenty patients with arterial hypertension and albuminuria (some amount of albumin in urine) are given valsartan 80 mg and then160 mg to normalize blood pressure.
- Trial name
- NCT00171353
- Testing
- valsartan
- Where
- Switzerland
- Volunteers
- 109 people
- Sponsor
- Novartis
Diabetic Nephropathies, Hypertension
Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients
The study consists of a 12 week run-in period when all subjects are stabilized on a single dose of Avalide (300 mg/12.5 mg or 300mg/25mg dose) per day.
- Trial name
- CARDINAL (NCT00713011)
- Testing
- Adalat XL, Tiazac XC
- Sponsor
- Bayer
Chronic Kidney Disease
Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients
The purpose of this study is to ascertain whether Arotinolol Hydrochloride reduces mortality and cardiovascular events in chronic kidney disease stage 5 patients with hypertension.
- Trial name
- AHOCEP (NCT01351636)
- Testing
- Arotinolol Hydrochloride, Non arotinolol group
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Diabetes Type 2
Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
This study will assess the reno-protective effect of renin inhibition with aliskiren as an alternative to irbesartan in type 2 diabetes patients with incipient/overt diabetic nephropathy.
- Trial name
- NCT00464880
- Testing
- Aliskiren
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Novartis
Diabetic Nephropathies, Hypertension
1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy
The general aim of this study is to compare telmisartan 80 mg with valsartan 160 mg in hypertensive patients with type 2 diabetes and overt nephropathy with adjusted blood pressure beyond the target of 130/80 mmHg after one year…
- Trial name
- NCT00153023
- Testing
- Telmisartan, Valsartan
- Where
- 111 sites in Czechia, Denmark and 11 more
- Volunteers
- 885 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Hypertension
Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes
The primary objective is to evaluate the effect of 9 weeks treatment with either telmisartan or ramipril on NO bioavailability in the renal vasculature, measured as renal plasma flow (RPF) in response to NG-monomethyl-L-arginine…
- Trial name
- NCT00240422
- Testing
- Telmisartan, Ramipril
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 96 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis
To evaluate the safety and efficacy, in particular with regard to renal function of telmisartan at the doses of 40 mg and 80 mg in hypertensive patients with moderate to endstage renal impairment after 12 weeks of treatment
- Trial name
- ESPRIT (NCT02178306)
- Testing
- Telmisartan low dose, Telmisartan high dose
- Volunteers
- 82 people
- Sponsor
- Boehringer Ingelheim
Hypertensive Nephropathy, Auto Immune Disorders
ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
This study investigates the safety and efficacy of ACE Reno, an oral transmucosal solution containing standardized bioactive peptides and amino acids, in patients with nephropathy of various etiologies and stages.
- Conditions
- Hypertensive Nephropathy, Auto Immune Disorders, Chronic Kidney Disease, Chronc Kidney Disease Stage 5
- Trial name
- ACE Reno (NCT07187713)
- Testing
- ACE Reno
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Ace Cells Lab Limited
Non-diabetic Nephropathy With Hypertension
ARIA (Atacand Renoprotection In NephropAthy Pt.)
To determine the effective dose of candesartan cilexetil for reduction of urinary protein excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline urinary protein/creatinine ratio between 500mg/g…
- Trial name
- PCR (NCT00573430)
- Testing
- Candesartan Cilexetil, Candesartan Cilexetil 32mg
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Hypertension
Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria
To examine antihypertensive effect and safety of administration of CS-3150 in combination with ARB or ACE inhibitor in hypertensive patients with type 2 diabetes and albuminuria.
- Trial name
- NCT02807974
- Testing
- CS-3150
- Where
- Japan
- Volunteers
- 51 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Proteinuria
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
- Trial name
- NCT05314231
- Testing
- ALXN1720
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Kidney Failure
Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD
The aim of this study is to assess the superiority of the new low sodium peritoneal dialysis (PD) solution PDsol 12 in comparison with a conventional, already marketed solution, Gambrosol trio 40, in the treatment of the…
- Trial name
- PDOne (NCT00794326)
- Testing
- Solution for Peritoneal Dialysis
- Where
- 29 sites in Denmark, France and 3 more
- Volunteers
- 140 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Hypertension
SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction
Assessing the safety, efficacy and pharmacokinetics of SPP100 (Aliskiren) regimen in hypertensive patients with renal dysfunction
- Trial name
- NCT00299832
- Testing
- Aliskiren
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Novartis
Safety
Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease
The purpose of this study is to evaluate long term safety and tolerability of azilsartan medoxomil and chlorthalidone, once daily (QD), compared with olmesartan medoxomil and hydrochlorothiazide in hypertensive participants with…
- Trial name
- NCT01309828
- Testing
- Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil and hydrochlorothiazide
- Where
- 53 sites in Bulgaria, Germany and 6 more
- Volunteers
- 153 people
- Sponsor
- Takeda
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.